Portfolio news

We’re excited to have Cancentus join our portfolio. Cancentus, a spin-off from the University of Geneva and the University of Basel, is exploiting oncogene-induced DNA…

Building on a strong collaboration, Lonza and BaseLaunch have renewed their partnership to further support the development of innovative therapeutics. As a Domain Partner, Lonza…

Basel, Switzerland, March 23, 2026 – Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of…

We are delighted to announce that Vossius is continuing its partnership with BaseLaunch to support cutting-edge early-stage biotechs in protecting and strengthening their innovations, helping…

We’re excited to welcome Umlaut.bio to our portfolio. Umlaut.bio, a spin-off from EMBL in Heidelberg, is pioneering the development of small molecules inhibiting tRNA modifications…

Basel, February 18th, 2026 - FimmCyte AG (“FimmCyte”), a pioneering Swiss biotech developing targeted immunotherapies for chronic fibro-inflammatory diseases, announces a strategic research collaboration and…

Basel, Switzerland - February 10, 2026 — BaseLaunch, a platform partnering with scientists and entrepreneurs to launch, fund, and build early biotech ventures, announced today the…

We are pleased to announce a partnership with Catalent, Inc., a global contract development and manufacturing organization (CDMO) supporting pharmaceutical, biotech and consumer health companies…

Basel, Switzerland - December 16, 2025 — BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has…

Basel, Switzerland - 11 December 2025, Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters…